A Study to Evaluate the Safety and Effectiveness of Rivaroxaban (Xarelto) for Prevention of Stroke and Systemic Embolism in Indian Patients With Non-valvular Atrial Fibrillation (NVAF)

NCT03887780 · clinicaltrials.gov ↗

COMPLETED

Status

504

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-valvular Atrial Fibrillation (NVAF)

Interventions

DRUG: Rivaroxaban (Xarelto,Bay 59-7939)

Sponsor

Bayer

Collaborators

[object Object]